Migraines are a common chronic neurological disorder characterized by moderate or severe pulsating headache attacks along with a number of autonomic nervous system symptoms. These symptoms may emerge as nausea, vomiting, sensitivity to light (photophobia), and/or increased sensitivity to sound (phonophobia). L-lysine clonixinate (lysine clonixinate) is a form of L-lysine amino acid and may be able to help with migraines.
Migraines can last anywhere from two to 72 hours and are usually treated with nonsteroidal anti-inflammatory drugs or analgesic drugs such as ibuprofen and paracetamol, and antiemetic drugs for nausea. It is estimated that 15% of the population suffer from migraines.
Researchers at the Headache Center of Rio in Brazil evaluated the efficacy and safety of an intravenous administration of L-lysine clonixinate and dipyrone for the treatment of severe headaches. L-lysine clonixinate is a form of amino acid L-lysine that is derived from nicotinic acid and serves as safe anti-inflammatory and analgesic compound. Dipyrone is a fast-acting non-opiate analgesic drug that is a common form of migraine treatment for emergency departments of Brazil.
What is L-Lysine Good for?
For the experiment researchers Abouch Krymchantowski, Henrique Carneiro, Jackeline Barbosa and Carla Jevoux recruited 30 participants from 18 to 48 years who have complaints of migraines. The subjects were split into two groups and given either L-lysine clonixinate (21 mL of 0.9% saline and 4 mL of 200 mg L-lysine clonixinate) or dipyrone (23 mL of 0.9% saline and 2 mL of 1000 mg dipyrone) for treatment of their severe migraine attack. Saline solution was used to dilute the drugs since a burning sensation at the site of injection is a common effect of L-lysine clonixinate. At half-hour intervals after administration of the injection, headache intensity, nausea, photophobia and other side effects were measured and recorded.
After evaluating the data, researchers Krymchantowski, Carneiro, Barbosa and Jevoux found at 30 minutes after injection, 0% of the dipyrone group and 13% of the L-lysine clonixinate group were free of migraine pain. At the 60-minute mark, pain free participants had increased to 13% of the dipyrone group and 73% of the L-lysine clonixinate group.
By the end of the 90-minute treatment, 33% of the dipyrone participants were pain free while almost 87% of the L-lysine clonixinate participants were free from migraine pain. Both drugs were effective in relieving nausea and photophobia by the end of treatment but more side effects, especially burning at the site of injection, was reported for the L-lysine clonixinate group.
Based on these results, the researchers conclude that L-lysine clonixinate may be a better option for treating severe migraine attacks, particularly when other drugs have shown to be ineffective for the patient.